July 24th, 2024 | 06:30 CEST
BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions
Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.
time to read: 3 minutes
|
Author:
Fabian Lorenz
ISIN:
BIONTECH SE SPON. ADRS 1 | US09075V1026 , BAYER AG NA O.N. | DE000BAY0017 , VIDAC PHARMA HOLDING PLC | GB00BM9XQ619
Table of contents:

"[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
Vidac Pharma: Cancer drug with billion-dollar potential
Can Vidac Pharma's share multiply? Yes, say the analysts at Sphene Capital. The Company is focusing its cancer research on reversing the "Warburg effect." The therapies developed aim to fight cancer by reversing the abnormal metabolism of cancer cells. This would allow Vidac to develop an entirely new class of cancer drugs.
Vidac's most advanced drug candidate is VDA-1102, which is designed to fight mycosis fungoides, a cancer of the white blood cells known as lymphocytes. VDA-1102 is already in clinical Phase 2a. After positive interim results were reported at the beginning of 2024 based on 50% of the test subjects, the final results are expected to be published by the end of the year.
If VDA-1102 receives approval in 2027, Sphene Capital expects the Vidac share price to reach EUR 4.90 in a base-case scenario. The share is currently trading at EUR 0.25. The price target is based on a three-stage discounted cash flow entity model as the primary valuation method. Following approval, analysts expect a rapid increase in revenue. Cumulative revenue should exceed EUR 1 billion within a few years, and the EBIT margin should rise to over 50%. Vidac Pharma's market capitalization is currently below EUR 10 million. The complete study is available for download here.
BioNTech: Finally, a "Buy" recommendation
When will the BioNTech share leave the downward trend? Shareholders of the Mainz-based company have been asking themselves this question for a long time and have likely been waiting just as long for a "Buy" recommendation. After numerous "Hold" recommendations, the first analyst has finally come out of the woodwork.
Baader Bank recommends buying the shares of the German biotech flagship. BioNTech is currently in a transition phase. While sales of the Corona vaccine continue to decline, it will still take time to generate revenue from cancer drugs. In order to make faster progress with the research pipeline, BioNTech will invest a total of around EUR 1.5 billion more than previously assumed in the current year and next year. Losses are likely to be correspondingly higher in these years. The share is nevertheless a "Buy", given the current price of EUR 79. The analysts' target price is EUR 151.
This means that the analysts at Baader are significantly more optimistic than their colleagues at Goldman Sachs, UBS, or Deutsche Bank. Their price targets range from EUR 90 to EUR 101. For them, BioNTech shares are merely a holding position.
Bayer shares: Only EUR 30 in it?
While an analyst finally recommends buying BioNTech again, experts are holding back on Bayer. Yesterday, JPMorgan pointed out that important data from the pharmaceutical pipeline is to be expected soon, including an update on Kerendia for chronic kidney disease in patients with heart failure. This has the potential to generate billions in sales and is therefore important for Bayer to compensate for the declining revenues from the blood coagulant Xarelto. However, the analysts currently see no reason to buy Bayer shares. Their price target is EUR 30 and thus barely above the current level.
The pharmaceutical pipeline was also a focus in the update from Goldman Sachs. Due to recently published Phase 3 data, Bayer in Leverkusen can hope for an expanded approval for its prostate cancer drug, Nubeqa. However, the impact on revenue and profits should not be overestimated. Nubeqa is already a blockbuster with an annual revenue of over EUR 1 billion for Bayer. The additional revenue potential from the extension of the marketing authorization is limited, as there are already approved drugs from competitors in this segment. Goldman Sachs, therefore, maintains its "Neutral" rating for Bayer shares, with a target price of EUR 30.
BioNTech currently lacks the momentum to establish a real upward trend, even if the market capitalization of around USD 20 billion does not appear too high, given the cash position and the long-term opportunities of the pipeline. In contrast, Vidac Pharma could see a stronger price jump at any time. If the next data are positive again, and the market capitalization remains low, takeover fantasy is likely to arise, too.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.